FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia1. Issue 1 (31st October 2012)

• Record Type: Journal Article
• Authors: Daver, Naval; Strati, Paolo; Jabbour, Elias; Kadia, Tapan; Luthra, Raja; Wang, Sa; Patel, Keyur; Ravandi, Farhad; Cortes, Jorge; Qin Dong, Xiao; Kantarjian, Hagop; Garcia‐Manero, Guillermo
• Is Part Of: American journal of hematology. Volume 88:Issue 1(2013:Jan.)
• Page Start: 56
• Page End: 59
• Publication Date: 2012-10-31
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.23345
• Languages: English
• ISSNs: 0361-8609

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>FMS‐like tyrosine kinase III (<italic>FLT3</italic>) mutations occur in one‐third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of <italic>FLT3</italic> in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with <italic>FLT3</italic> mutations at diagnosis. A total of 2, 119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, <italic>FLT3</italic> mutation analysis was performed on 1, 232 (58%) MDS and 302 (65%) CMML patients. <italic>FLT3</italic> mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had <italic>FLT3‐ITD</italic> mutation and 3 had <italic>FLT3‐</italic>tyrosine kinase domain (<italic>TKD</italic>) mutation. MDS patients with <italic>FLT3</italic> mutations were younger (<italic>P</italic> = 0.02) and presented as RAEB (<italic>P</italic> = 0.03) more frequently. Median overall survival (OS) for <italic>FLT3</italic>‐mutated MDS patients was 19.0 months versus 16.4 months for <italic>FLT3</italic>‐nonmutated MDS patients (<italic>P</italic> = 0.08). <italic>FLT3</italic> mutations were identified in 13 (4.3%) CMML patients: 8 had <italic>FLT3‐ITD</italic> mutation and 5 had <italic>FLT3‐TKD</italic> mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without <italic>FLT3</italic> mutations. Median OS for <italic>FLT3</italic>‐mutated CMML patients was 10.8 months versus 21.3 months for <italic>FLT3</italic>‐nonmutated CMML patients (<italic>P</italic> = 0.12). <italic>FLT3</italic> occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome. Am. J. Hematol. 2013. © 2012 Wiley Periodicals, Inc.</p> </abstract>